PerturbAI publicly released an in vivo Perturb‑seq dataset mapping gene function across 8 million brain cells, produced with partners including 10x Genomics, NVIDIA and the Allen Institute. The atlas links CRISPR perturbations to cell‑type and circuit‑level effects and is aimed at accelerating target validation and AI model training for therapeutic discovery. Concurrently, Xaira detailed X‑Cell, an AI model that predicts virtual cell states for use in in silico screening and R&D. Both releases signal growing industry reliance on large, publicly available functional genomics datasets and generative AI models to triage targets and simulate interventions before preclinical testing.